Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Obtains Broader Label For Denosumab With Oncology Indication

Executive Summary

FDA approved Amgen’s bone-strengthening drug denosumab Nov. 18 for its first oncology indication, prevention of skeletal-related events – bone fractures or bone pain requiring radiation treatment – in patients with bone metastases from solid tumors.
Advertisement

Related Content

On Amgen’s Agenda: Bring Biologics To Primary Care
Amgen Needs To Show Xgeva Does More Than Delay Bone Metastases, ODAC Says
New Oncology Indications Should Continue Denosumab’s Upward Trajectory
New Oncology Indications Should Continue Denosumab’s Upward Trajectory
New Oncology Indications Give Amgen's Bone Drug Denosumab A Bit Of A Leg Up
Amgen's Bone Drug Xgeva Delays Pain From Prostate Cancer Metastases
Amgen Shifts Its Focus From Products To Pipeline, But Stays In Comfort Zone
Amgen Shifts Its Focus From Products To Pipeline, But Stays In Comfort Zone
Pediatric Oncology Panel Highlights Trend Toward Being More Selective With Studies
FDA Okays Amgen's Prolia, But With Hefty Post-Marketing Requirements In Tow

Topics

Advertisement
UsernamePublicRestriction

Register

PS052845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel